Viewing Study NCT05607433


Ignite Creation Date: 2025-12-25 @ 2:49 AM
Ignite Modification Date: 2025-12-26 @ 1:30 AM
Study NCT ID: NCT05607433
Status: UNKNOWN
Last Update Posted: 2022-11-07
First Post: 2019-09-13
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Air Q Laryngeal Airway Versus the AmbuAura Gain as a Conduit for Endotracheal Intubation
Sponsor: Cairo University
Organization:

Study Overview

Official Title: Air Q Intubating Laryngeal Airway (Air QILA) Versus the AmbuAura Gain as a Conduit for Endotracheal Intubation Assisted by Tube Exchanger, a Randomized Comparative Study.
Status: UNKNOWN
Status Verified Date: 2022-11
Last Known Status: NOT_YET_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The study aims to compare the efficacy of the Ambu AuraGain to that of the Air Q ILA as a conduit for endotracheal intubation assisted by tube exchanger. The comparison will be in terms of total intubation time, success rate of insertion of the tube exchanger as well as endotracheal intubation and complications.
Detailed Description: Very few studies discussed assisted endotrachealc intubation using certain tools as bougie through the Air Q ILA .

the hypothesis in this study is that the use of flexible, small calibre tube exchanger introduced through both supraglottic devices into the trachea as guidance for endotracheal intubation, will have shorter intubation time with the Ambu AuraGain than the Air Q ILA and less complications in both devices.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: